Clinical

Dataset Information

0

The Effects of Curcumin on Patients with Colorectal Cancer


ABSTRACT: Intervention 1: Intervention group: Subjects in the intervention group receive curcumin-piperine capsules (daily intake of 500 mg curcumin plus 5 mg piperine) for 8 weeks (n=36). The participants take one capsule every day, which was contained in an unlabeled bottle. Capsules are from Sami Labs company (Bangalore, India). Intervention 2: Control group: Placebo capsules are prepared by a similar company and are similar to the curcumin capsules regarding the color, shape and size. The control group receive a placebo capsule containing lactose plus 5 mg piperine for a period of 8 weeks (n=36). The participants take one capsule every day, which was contained in an unlabeled bottle. Capsules are from Sami Labs company (Bangalore, India). Primary outcome(s): Tumor necrosis factor alpha. Timepoint: Before the intervention and 8 weeks after taking drug or placebo. Method of measurement: Sandwich and competitive chemiluminescence immunoassays.;Interleukin 6. Timepoint: Before the intervention and 8 weeks after taking drug or placebo. Method of measurement: Sandwich and competitive chemiluminescence immunoassays.;Total quality of life score. Timepoint: Before the intervention and 8 weeks after taking drug or placebo. Method of measurement: Using EORTC QLQ questionnaire. Study Design: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were randomly assigned to one of the treatment groups based on random allocation sequence generated by a statistician: 1) Drug: a group receiving liposomal curcumin capsules (500 mg/day) for 8 weeks (n=36), 2) Placebo: the control group who taking a placebo capsule for a period of 8 weeks (n=36).The tables of the Fleiss book were used to generate the random allocation sequence. The allocation scheme was consecutively numbered in envelopes which opened sequentially by an independent person, not involved in the study, Blinding description: All volunteers, care providers and statistician were blinded after assignment to intervention. So that, the capsules containers were coded as A and B by a non-researcher person and remained confidential until statistical analysis. The placebo capsules were similar to the drugs regarding the weight and c

DISEASE(S): Malignant Neoplasm Of Rectosigmoid Junction,Colorectal Cancer

PROVIDER: 2475013 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-11-23 | GSE140874 | GEO
2014-05-01 | E-GEOD-48368 | biostudies-arrayexpress
2024-01-01 | GSE223970 | GEO
2022-03-31 | GSE193773 | GEO
| 2475478 | ecrin-mdr-crc
2012-05-29 | E-GEOD-34898 | biostudies-arrayexpress
| 2688440 | ecrin-mdr-crc
2014-01-03 | E-GEOD-43266 | biostudies-arrayexpress
2014-02-21 | GSE55196 | GEO
| 2492862 | ecrin-mdr-crc